P
Phillip A. Sharp
Researcher at Massachusetts Institute of Technology
Publications - 618
Citations - 125567
Phillip A. Sharp is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: RNA & Gene. The author has an hindex of 172, co-authored 614 publications receiving 117126 citations. Previous affiliations of Phillip A. Sharp include McGovern Institute for Brain Research & Medical Research Council.
Papers
More filters
Journal ArticleDOI
Requirement for distal upstream sequences for maximal transcription in vitro of early region IV of adenovirus.
Hiroshi Handa,Phillip A. Sharp +1 more
TL;DR: A series of deletion mutants spanning the adenovirus early region IV (EIV) promoter were tested for transcription activity in vitro and sequences residing upstream from -140 critically influence the level of EIV transcription.
Journal ArticleDOI
Splicing messenger RNA precursors: branch sites and lariat RNAs
TL;DR: The splicing of mRNA precursors proceeds through an unusual RNA structure: a lariat or tailed circular molecule where the 5′ end of the intervening sequence is attached to an internal residue via a 2′–5′ phosphodiester bond.
Journal ArticleDOI
Iron bioavailability from commercially available iron supplements
TL;DR: In the in vitro model, naturally iron-rich mineral waters and synthetic liquid iron formulations have equivalent or better bioavailability compared with ferrous iron sulphate tablets, which would mean that at-risk groups of IDA could be offered a greater choice of more bioavailable and potentially better tolerated iron preparations.
Journal ArticleDOI
Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1-3 family.
Courtney K. JnBaptiste,Allan M. Gurtan,Kevin K. Thai,Victoria Lu,Arjun Bhutkar,Mei-Ju Su,Asaf Rotem,Tyler Jacks,Phillip A. Sharp +8 more
TL;DR: This analysis uncovers a miRNA-repressed network containing oncofetal genes Imp1, Imp2, and Imp3 (Imp1-3) that is up-regulated primarily transcriptionally >100-fold upon Dicer loss and is resistant to resilencing by complete restoration of miRNA activity.
Journal ArticleDOI
In vitro assessment of iron availability from commercial Young Child Formulae supplemented with prebiotics
TL;DR: The results suggest that ascorbic acid and prebiotics in YCF improve iron bioavailability, and ensuring that iron is delivered in a bioavailable form would improve the nutritional benefits of YCF in relation to ID/IDA amongst young children.